PRNewsWire
08 Jan 2026, 14:00 UTC · 38w ago
Verdict
Headline leans bearish. We score ATRA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
A securities fraud class action lawsuit alleges that Skye Bioscience's lead product candidate, nimacimab, was less effective than the company represented to investors.
So whatA credible allegation that a biotech's lead asset lacks the efficacy previously communicated severely undermines the company's core valuation and future revenue potential.
More negative than 99% of claims this week
The lawsuit alleges that nimacimab's clinical, regulatory, and commercial prospects were overstated by the company during the class period.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 98% of claims this week
Shareholders who purchased SKYE between November 4, 2024, and October 3, 2025 face a January 16, 2026 deadline to seek lead plaintiff appointment in the class action.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is mentioned as the subject of a class action lawsuit with a lead plaintiff deadline.
More negative than 95% of ticker scores this week
The company is mentioned as the subject of a class action lawsuit.
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit alleging misleading statements about its lead product candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
10h ago
−34.7%
Price agrees with the score
$9.75 vs $14.94 close before publication (Jan 7) · not market-adjusted
ATRA chart →
